Data / Drug companies / Harrow Eye, LLC
Harrow Eye, LLC: 17 products in the FDA NDC directory, labeler code 82667
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Harrow Eye, LLC (labeler code 82667) lists 17 products in the FDA National Drug Code Directory, covering 16 finished drugs by generic name. By type: 16 prescription drugs, 1 over the counter drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on January 1, 2026.
The request: Watch Harrow Eye, LLC (FDA labeler code 82667): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 82667
- Products in commercial distribution
- 17
- Packages
- 25
- Finished drugs by generic name
- 16
- Prescription products
- 16
- Over the counter products
- 1
- Flagged as original packager
- 17 of 17 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- November 15, 1964
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 15 | 88.2% |
| Biologics (BLA) | 1 | 5.9% |
| Over the counter monograph drugs | 1 | 5.9% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 16 | 94.1% |
| Over the counter drugs | 1 | 5.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Nepafenac | 2 | 2 |
| Ranibizumab-nuna | 1 | 2 |
| Chloroprocaine hydrochloride ophthalmic gel | 1 | 1 |
| Fluorometholone acetate | 1 | 2 |
| Natamycin | 1 | 2 |
| Cetirizine | 1 | 5 |
| Triamcinolone acetonide | 1 | 77 |
| Povidone, polyvinyl alcohol solution | 1 | 1 |
| Neomycin sulfate, polymyxin b sulfate and dexamethasone | 1 | 11 |
| Cyclosporine ophthalmic solution | 1 | 1 |
| Tobramycin / dexamethasone | 1 | 2 |
| Cyclosporine | 1 | 24 |
| Dexamethasone | 1 | 45 |
| Clobetasol propionate | 1 | 40 |
| Apraclonidine hydrochloride ophthalmic solution | 1 | 1 |
| Moxifloxacin hydrochloride | 1 | 20 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Suspension/ drops | 5 | 29.4% |
| Solution/ drops | 4 | 23.5% |
| For suspension | 2 | 11.8% |
| Injection, solution | 1 | 5.9% |
| Gel | 1 | 5.9% |
| For solution | 1 | 5.9% |
| Injection, suspension | 1 | 5.9% |
| Suspension | 1 | 5.9% |
| Emulsion | 1 | 5.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Byooviz | 82667-018 | Injection, solution | Biologics (BLA) | January 1, 2026 |
| Zerviate | 82667-015 | For solution | New drug applications (NDA) | April 30, 2025 |
| Maxidex | 82667-600 | For suspension | New drug applications (NDA) | April 7, 2025 |
| Tobradex ST | 82667-011 | Suspension/ drops | New drug applications (NDA) | March 31, 2025 |
| Flarex | 82667-010 | Suspension/ drops | New drug applications (NDA) | March 31, 2025 |
| Nevanac | 82667-500 | Suspension/ drops | New drug applications (NDA) | January 1, 2025 |
| Natacyn | 82667-012 | Suspension/ drops | New drug applications (NDA) | November 1, 2024 |
| Triesence | 82667-800 | Injection, suspension | New drug applications (NDA) | October 1, 2024 |
| Vigamox | 82667-700 | Solution/ drops | New drug applications (NDA) | July 1, 2024 |
| Ilevro | 82667-400 | Suspension/ drops | New drug applications (NDA) | May 1, 2024 |
| Byqlovi | 82667-021 | For suspension | New drug applications (NDA) | March 4, 2024 |
| Vevye | 82667-900 | Solution/ drops | New drug applications (NDA) | December 1, 2023 |
| Freshkote preservative free lubricant eye drops | 82667-013 | Solution/ drops | Over the counter monograph drugs | September 15, 2023 |
| Iopidine 1% | 82667-200 | Solution/ drops | New drug applications (NDA) | August 1, 2023 |
| Iheezo | 82667-300 | Gel | New drug applications (NDA) | September 27, 2022 |
| Verkazia | 82667-014 | Emulsion | New drug applications (NDA) | February 1, 2022 |
| Maxitrol | 82667-100 | Suspension | New drug applications (NDA) | November 15, 1964 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.